2nd Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Supported HR 5389, "Medicare Clinical Pharmacist Practitioner Services Coverage Act of 2010," all provisions. Labor-Health and Human Services Appropriations fiscal years 2010 and 2011. H.R. 3590, Patient Protection and Affordable Care Act, Title III, all provisions relating to "medication therapy management," "medical home," and "independence at home." Communication to HHS regarding strategic framework on multiple chronic conditions; Communication to FDA on direct-to-consumer prescription drug advertisements; Meeting with AHRQ to discuss comparative effectiveness research.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Food & Drug Administration (FDA); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Drug Enforcement Administration (DEA)

Bills named: H.R. 3590 (111th), H.R. 5389 (111th)

Medicare/Medicaid MMM

Communication with CMS on funding for specialized pharmacy residency programs; communication with the Office of the National Coordinator for Health Information Technology on certification programs for health information technology; communication to CMS regarding counseling to prevent tobacco use; communication to CMS on the hospital inpatient prospective payment system.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Drug Enforcement Administration (DEA); Agency for Healthcare Research & Quality (AHRQ); SENATE

Pharmacy PHA

Communications with FDA on Risk Evaluation and Mitigation Strategies and Prescription Drug User Fee Act reauthorization; communication with Office of Pharmacy Affairs, Health Resources and Services Administration on 340B drug pricing program, transition to new Director of Office of Pharmacy Affairs, Patient Safety and Clinical Services Collaborative, status of patient definition guidelines, increased federal funds for community health centers, National Healthcare Workforce Commission; Commmunication with FDA on distribution of medication guides in the inpatient setting; communication with FDA on drug recalls; communication with DEA on electronic prescriptions for controlled substances; meeting with HRSA's Office of Rural Health Policy to discuss medication therapy management, workforce commission, patient safety collaborative, telepharmacy, 340B and health IT.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); SENATE; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.